Histopathological changes in parotid gland following submandibular gland failure: an experimental animal study

Yildirim, Yavuz Sultan Selim; Kaygusuz, İrfan; Ozercan, İbrahim Hanifi; Çetiner, Hasan; Sakallıoğlu, Öner; Akyiğit, Abdulvahap; Düzer, Sertaç

doi:10.1016/j.bjorl.2018.03.013

Cited by 2 publications

(3 citation statements)

References 15 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study mentioned dilated ducts and more mucus accumulation in parotid glands after resection of the submandibular glands in rabbits. 20 Another study revealed increased parotid salivary flow rate after botulinum neurotoxin A injections in the submandibular glands, which indicated parotid gland compensation. 13 Correspondingly, most children in our study received onabotulinum neurotoxin A injections in the submandibular glands only, leaving the parotid glands untreated, which could have led to compensational hypersalivation of the alternative glands.…”

Section: Discussionmentioning

confidence: 99%

“…Another explanation for the decrease in effect could be parotid compensational hypersalivation. One study mentioned dilated ducts and more mucus accumulation in parotid glands after resection of the submandibular glands in rabbits 20 . Another study revealed increased parotid salivary flow rate after botulinum neurotoxin A injections in the submandibular glands, which indicated parotid gland compensation 13 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Repeated onabotulinum neurotoxin A injections for drooling in children with neurodisability

Bekkers¹,

Leow²,

Hulst

et al. 2021

Develop Med Child Neuro

View full text Add to dashboard Cite

NabNeutralizing antibodies VAS Visual analogue scale AIM To evaluate the effect of repeated onabotulinum neurotoxin A injections for the treatment of drooling in children with neurodisabilities.METHOD This was a retrospective cohort study, in which the first, second, and third onabotulinum neurotoxin A injection were compared within children treated between 2000 and 2020. Primary outcomes included drooling quotient, visual analogue scale (VAS), and treatment success defined as ≥50% reduction in drooling quotient and/or VAS 8 weeks after treatment. Each outcome was obtained at baseline and 8 weeks posttreatment.RESULTS Seventy-seven children were included (mean age at first injection: 8y 3mo, SD 3y 7mo, range 3-17y; 44 males, 33 females; 51.9% with cerebral palsy, 45.5% wheelchair-bound).The objective (drooling quotient) and subjective (VAS) effect after the second injection was lower compared to the first injection. The third injection showed less objective and significantly less subjective effect compared to the first injection. An overall success rate of 74.0%, 41.6%, and 45.8% were found for the first, second, and third injection respectively.INTERPRETATION Although onabotulinum neurotoxin A remained effective throughout the entire treatment course, there is less effect of subsequent onabotulinum neurotoxin A injections compared to the first. Although there might be a loss of effect after repeated injections, there is continued improvement for most children.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Repeated onabotulinum neurotoxin A injections for drooling in children with neurodisability

Bekkers¹,

Leow²,

Hulst

et al. 2021

Develop Med Child Neuro

View full text Add to dashboard Cite

show abstract

“…A significant number of COVID-19 survivors (prevalence of 37.7%) developed salivary gland ectasia [16] that was considered to reflect the hyperinflammatory response to SARS-CoV-2 infection because of significant relations with C-reactive protein and lactate dehydrogenase levels at hospital admission. The main ductal ectasia of salivary gland is one of histopathological changes in Sjögren's syndrome and infectious diseases [63].…”

Section: Salivary Gland Inflammationmentioning

confidence: 99%

Characterization and Pathogenic Speculation of Xerostomia Associated with COVID-19: A Narrative Review

Tsuchiya

2021

Dentistry Journal

View full text Add to dashboard Cite

Patients with coronavirus disease 2019 (COVID-19) have become known to present with different oral symptoms. However, xerostomia remains poorly recognized compared with taste dysfunction. For better understanding of COVID-19 symptomatology, xerostomia associated withCOVID-19 was characterized and its possible pathogenesis was speculated by a narrative literature review. Scientific articles were retrieved by searching PubMed, LitCovid, ProQuest, Google Scholar, medRxiv and bioRxiv from 1 April 2020 with a cutoff date of 30 September 2021. Results of the literature search indicated that xerostomia is one of prevalent and persistent oral symptoms associated with COVID-19. In contrast to taste dysfunction, the prevalence and persistence of xerostomia do not necessarily depend on ethnicity, age, gender and disease severity of patients. COVID-19 xerostomia is pathogenically related to viral cellular entry-relevant protein expression, renin-angiotensin system disturbance, salivary gland inflammation, zinc deficiency, cranial neuropathy, intercurrent taste dysfunction, comorbidities and medications. Despite a close association with COVID-19, xerostomia, dry mouth and hyposalivation tend to be overlooked unlike ageusia, dysgeusia and hypogeusia. Although mouth dryness per se is not life-threating, it has an impact on the oral health-related quality of life. More attention should be paid to xerostomia in COVID-19 patients and survivors.

show abstract

Histopathological changes in parotid gland following submandibular gland failure: an experimental animal study

Abstract: The findings of this study indicate that only 1 month after submandibular gland failure, the parotid glands exhibit significant changes.

Cited by 2 publications

References 15 publications

Repeated onabotulinum neurotoxin A injections for drooling in children with neurodisability

Repeated onabotulinum neurotoxin A injections for drooling in children with neurodisability

Characterization and Pathogenic Speculation of Xerostomia Associated with COVID-19: A Narrative Review

Contact Info

Product

Resources

About